Federal Contractor Profile
Resilience Government Services, INC.
Federal contracting record: $292M obligated across 18 awards from 2 agencies, FY 2016–2026.
Company Profile
Parent UEI (Unique Entity Identifier)
GC2RFAZK8G64
CAGE Code
3GQS9
Address
13200 NW NANO CT, ALACHUA, FL, 32516
First Federal Award
Oct 13, 2015
Most Recent Award
Aug 20, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Defense$267M
91.5% of total obligations
- Department of Health and Human Services$25M
8.5% of total obligations
Top NAICS Activity
- $165M
- 541715$102M
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
4 awards
- $16M
- $8.4M
- $1.2M
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Sep 23, 2025 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $1.6M |
| Sep 10, 2024 | Department of DefenseW6QK ACC-APG | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $4.5M |
| Jul 31, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $750K |
| Jun 25, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT | $314K |
| May 23, 2024 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $9.0M |
| Mar 28, 2024 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $3.0M |
| Mar 26, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $473K |
| Feb 21, 2024 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $9.1M |
| Nov 2, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DS PROCESS CHARACTERIZATION | $1000K |
| Nov 1, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $2.2M |
| Oct 30, 2023 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $2.8M |
| Sep 25, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $489K |
| Sep 12, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.8M |
| Aug 25, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT | $485K |
| Aug 17, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $135K |
| Aug 8, 2023 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $4.8M |
| Aug 3, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DS PROCESS CHARACTERIZATION | $1.1M |
| Aug 3, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $400K |
| Jun 29, 2023 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $4.4M |
| Jun 23, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $681K |
| Apr 12, 2023 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $9.8M |
| Mar 9, 2023 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $12M |
| Mar 8, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $4.4M |
| Mar 7, 2023 | Department of DefenseW6QK ACC-APG | 541715 | DS PROCESS CHARACTERIZATION | $2.0M |
| Feb 17, 2023 | Department of DefenseW6QK ACC-APG | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $5.6M |
Top Compensated Officers
From FFATA executive compensation disclosures. Reported when federal contract activity exceeds the statutory threshold.
- $554K
PETER H KHOURY
Rank 1 · Reported Sep 16, 2022
- $401K
JAMES M MATTHEW
Rank 2 · Reported Sep 16, 2022
- $372K
WILLIAM T HENSLER
Rank 3 · Reported Jul 16, 2018
- $345K
ROBERT V HOUSE
Rank 4 · Reported Sep 16, 2022
- $345K
MICHAEL T COOKE
Rank 5 · Reported Sep 16, 2022
Want to win work like Resilience Government Services, INC.?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.